Merck (MRK) Reports Pivotal Phase III Data for BAVENCIO (avelumab) Plus INLYTA (axitinib) in Advanced RCC Published in New England Journal of Medicine (Earlier)

February 19, 2019 5:54 AM
Merck (NYSE: MRK) which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles